Long non-coding RNA <i>UCA1</i> induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in <i>EGFR</i>-mutant non-small cell lung cancer
Ningning Cheng(Tongji University), Fred R. Hirsch(Tisch Hospital), Caicun Zhou(Tongji University), Fei Ke(Chinese Academy of Sciences), Xuefei Li(Harbin Medical University), Hui Pan(Université Paris Cité), Jiayu Li(Tongji University), Chao Zhao(Tongji University), Xiaoxia Chen(Guangdong Academy of Medical Sciences), Qi Wang(Tongji University), Weijing Cai(Hebei Medical University), Shengxiang Ren(Tongji University), Mingchuan Zhao(Tongji University), Yishi Zhang(Tongji University)
Cited by 149
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|504